Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25382269 | 0.84 | APLNR (0.44) | TSHRAPLNRLMNANR1I2ABCB11 | |
| SCHEMBL6891911 | 0.82 | APLNR (0.31) | APLNRGAA | |
| SCHEMBL13148260 | 0.78 | TSHR (0.41) | TSHRAPLNRLMNAGAACYP1A2 | |
| SCHEMBL6335395 | 0.77 | SCN9A (0.37) | CYP1A2CYP2C19MEN1KMT2AHIF1A | |
| SCHEMBL6886867 | 0.77 | TSHR (0.33) | TSHRAPLNR | |
| SCHEMBL4629992 | 0.77 | LMNA (0.54) | APLNRLMNANR1I2ABCB11GAA | |
| SCHEMBL4629991 | 0.77 | LMNA (0.54) | APLNRLMNANR1I2ABCB11GAA | |
| SCHEMBL4630600 | 0.77 | LMNA (0.54) | APLNRLMNANR1I2ABCB11GAA | |
| SCHEMBL11591693 | 0.77 | LMNA (0.54) | APLNRLMNANR1I2ABCB11GAA | |
| SCHEMBL4629990 | 0.77 | LMNA (0.54) | APLNRLMNANR1I2ABCB11GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677331-B2 | HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20030149016-A1 | Novel carbapenem derivatives | KANO YUKO (JP) | 2003-08-07 | — | — | US | disclosed |
| EP-1101766-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149016-A1 | Novel carbapenem derivatives | DPEP1, TMPRSS15, STK35 | TSHR 4209/4885APLNR 4737/4885LMNA 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.